Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma

The phase 2/3 RELATIVITY-047 trial shows, that a combination of nivolumab & relatlimab significantly improved the primary endpoint of progression-free survival (PFS) versus monotherapy with nivolumab in patients with previously untreated metastatic or unresectable melanoma.